Literature DB >> 17785556

Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.

Gordon Strathdee1, Tessa L Holyoake, Alyson Sim, Anton Parker, David G Oscier, Junia V Melo, Stefan Meyer, Tim Eden, Anne M Dickinson, Joanne C Mountford, Heather G Jorgensen, Richard Soutar, Robert Brown.   

Abstract

PURPOSE: The HOX genes comprise a large family of homeodomain-containing transcription factors, present in four separate clusters, which are key regulators of embryonic development, hematopoietic differentiation, and leukemogenesis. We aimed to study the role of DNA methylation as an inducer of HOX gene silencing in leukemia. EXPERIMENTAL
DESIGN: Three hundred and seventy-eight samples of myeloid and lymphoid leukemia were quantitatively analyzed (by COBRA analysis and pyrosequencing of bisulfite-modified DNA) for methylation of eight HOXA and HOXB cluster genes. The biological significance of the methylation identified was studied by expression analysis and through re-expression of HOXA5 in a chronic myeloid leukemia (CML) blast crisis cell line model.
RESULTS: Here, we identify frequent hypermethylation and gene inactivation of HOXA and HOXB cluster genes in leukemia. In particular, hypermethylation of HOXA4 and HOXA5 was frequently observed (26-79%) in all types of leukemias studied. HOXA6 hypermethylation was predominantly restricted to lymphoid malignancies, whereas hypermethylation of other HOXA and HOXB genes was only observed in childhood leukemia. HOX gene methylation exhibited clear correlations with important clinical variables, most notably in CML, in which hypermethylation of both HOXA5 (P = 0.00002) and HOXA4 (P = 0.006) was strongly correlated with progression to blast crisis. Furthermore, re-expression of HOXA5 in CML blast crisis cells resulted in the induction of markers of granulocytic differentiation.
CONCLUSION: We propose that in addition to the oncogenic role of some HOX family members, other HOX genes are frequent targets for gene inactivation and normally play suppressor roles in leukemia development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785556     DOI: 10.1158/1078-0432.CCR-07-0919

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  56 in total

1.  Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome.

Authors:  Angela Di Vinci; Ida Casciano; Elena Marasco; Barbara Banelli; Gian Luigi Ravetti; Luana Borzì; Claudio Brigati; Alessandra Forlani; Alessandra Dorcaratto; Giorgio Allemanni; Gianluigi Zona; Renato Spaziante; Henning Gohlke; Giovanni Gardin; Domenico Franco Merlo; Vilma Mantovani; Massimo Romani
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-27       Impact factor: 4.553

Review 2.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

3.  A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma.

Authors:  Meena Kanduri; Birgitta Sander; Stavroula Ntoufa; Nikos Papakonstantinou; Lesley-Ann Sutton; Kostas Stamatopoulos; Chandrasekhar Kanduri; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-10-09       Impact factor: 4.528

4.  Array-based DNA methylation profiling of primary lymphomas of the central nervous system.

Authors:  Julia Richter; Ole Ammerpohl; José I Martín-Subero; Manuel Montesinos-Rongen; Marina Bibikova; Eliza Wickham-Garcia; Otmar D Wiestler; Martina Deckert; Reiner Siebert
Journal:  BMC Cancer       Date:  2009-12-21       Impact factor: 4.430

Review 5.  Uncovering the DNA methylome in chronic lymphocytic leukemia.

Authors:  Nicola Cahill; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-01-15       Impact factor: 4.528

6.  A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster.

Authors:  Xueqing Zhang; Zheng Lian; Carolyn Padden; Mark B Gerstein; Joel Rozowsky; Michael Snyder; Thomas R Gingeras; Philipp Kapranov; Sherman M Weissman; Peter E Newburger
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

7.  DNA methylation dynamics during in vivo differentiation of blood and skin stem cells.

Authors:  Christoph Bock; Isabel Beerman; Wen-Hui Lien; Zachary D Smith; Hongcang Gu; Patrick Boyle; Andreas Gnirke; Elaine Fuchs; Derrick J Rossi; Alexander Meissner
Journal:  Mol Cell       Date:  2012-07-26       Impact factor: 17.970

8.  Lsh mediated RNA polymerase II stalling at HoxC6 and HoxC8 involves DNA methylation.

Authors:  Yongguang Tao; Sichuan Xi; Victorino Briones; Kathrin Muegge
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

9.  The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores.

Authors:  Rafael A Irizarry; Christine Ladd-Acosta; Andrew P Feinberg; Bo Wen; Zhijin Wu; Carolina Montano; Patrick Onyango; Hengmi Cui; Kevin Gabo; Michael Rongione; Maree Webster; Hong Ji; James Potash; Sarven Sabunciyan
Journal:  Nat Genet       Date:  2009-01-18       Impact factor: 38.330

10.  Cancer genomics identifies regulatory gene networks associated with the transition from dysplasia to advanced lung adenocarcinomas induced by c-Raf-1.

Authors:  Astrid Rohrbeck; Jürgen Borlak
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.